| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
Hyperoxic lung injury is commonly encountered in patients
who require treatment with high concentrations of inspired
oxygen. To determine whether interleukin (IL)-6 is protective
in oxygen toxicity, we compared the effects of 100% O2 in
transgenic mice that overexpress IL-6 in the lung and transgene (
) controls. IL-6 markedly enhanced survival, with
100% of transgene (
) animals dying within 72 to 96 h, 100%
of transgene (+) animals living for more than 8 d and more
than 90% of transgene (+) animals living longer than 12 d.
This protection was associated with markedly diminished alveolar-capillary protein leak, endothelial and epithelial membrane injury, and lung lipid peroxidation. Hyperoxia also
caused cell death with DNA fragmentation in the lungs of
transgene (
) animals and IL-6 markedly diminished this cytopathic response. The protective effects of IL-6 were not associated with significant alterations in the activities of copper/
zinc superoxide dismutase (SOD) or manganese SOD. They
were, however, associated with the enhanced accumulation of
the cell-death inhibitor Bcl-2, but not the cell-death stimulator
BAX, and with the heightened accumulation of the cell-death
regulator tissue inhibitor of metalloproteinase-1 (TIMP-1).
These studies demonstrate that IL-6 markedly diminishes hyperoxic lung injury and that this protection is associated with a marked diminution in hyperoxia-induced cell death and
DNA fragmentation. They also demonstrate that this protection is not associated with significant alterations in SOD activity, but is associated with the induction of Bcl-2 and TIMP-1.
| |
Introduction |
|---|
|
|
|---|
Supplemental oxygen is commonly given to patients with cardiopulmonary disorders to enhance tissue oxygenation. Unfortunately, the prolonged administration of fractional inspired concentrations of oxygen greater than 50 to 60% leads to a variety of forms of tissue damage, including acute lung injury. The pathophysiology of this pulmonary toxicity has been characterized in animal models (1). These studies demonstrated that toxic concentrations of O2 generate oxygen-derived free radicals that damage lung epithelial and endothelial cells, leading to a protein-rich fluid that floods the alveolar space. Recent researchers have also demonstrated that this injury is associated with a cell-death response with features of both cell necrosis and apoptosis (4, 5).
Interleukin (IL)-6 is a pleiotropic cytokine that is produced at sites of tissue inflammation. It is classified as an
IL-6-type cytokine with IL-11, leukemia inhibitory factor,
cardiotrophin-1, oncostatin M, and ciliary neurotrophic factor on the basis of the overlapping effector profiles of these
cytokines and their shared use of gp130 as the
-subunit in
their multimeric receptor complexes (6). IL-6 induces fever,
activates B and T lymphocytes, and stimulates hepatocytes
to produce acute phase proteins. Recent studies have shown
that IL-6 also has potent anti-inflammatory and protective
properties. These include the ability to inhibit the production of tumor necrosis factor (TNF), IL-1, and macrophage inflammatory protein-2; decrease neutrophil sequestration;
increase levels of IL-1 receptor antagonist and TNF soluble
receptor; stimulate the production of metalloproteinase inhibitors; reduce intracellular superoxide production; reduce
tissue matrix degradation; and inhibit cellular apoptosis (7-
14). Surprisingly, the ability of IL-6 to regulate hyperoxic
lung injury has not been adequately investigated.
We hypothesized that the anti-inflammatory and cytoproptective effects of IL-6 could ameliorate hyperoxic
lung injury. To test this hypothesis we compared the injury
induced by 100% O2 in transgenic mice in which IL-6 was
selectively overexpressed in the lung (CC10-IL-6 mice)
with appropriate transgene (
) littermate controls. These
experiments demonstrated that CC10-IL-6 transgene (+)
mice have an impressive ability to tolerate 100% O2. This tolerance manifests as enhanced survival, decreased pulmonary edema and alveolar-capillary protein leakage, and
decreased lung lipid peroxidation when compared with
transgene (
) controls. Further, transgene (
) mice manifest an impressive cell-death response associated with
DNA fragmentation which was inhibited in the IL-6 (+)
animals. This protection was associated with the enhanced
accumulation of the regulatory proteins Bcl-2 and tissue inhibitor of metalloproteinase-1 (TIMP-1).
| |
Materials and Methods |
|---|
|
|
|---|
Generation of CC10-IL-6 Transgenic Mice
CC10-IL-6 transgenic mice were produced on a CBA × C57BL/6
background. In these mice the Clara cell 10-kD protein promoter (CC10) was used to overexpress IL-6 in a lung-specific fashion (in
Clara cells and, to a lesser degree, alveolar epithelial cells). This
results in 0.5 to 1.5 ng/ml levels of IL-6 in the animals' bronchoalveolar lavage (BAL) fluid (BALF). The methods used by our
laboratory to generate these mice, the organ specificity of transgene targeting, and the pathologic alterations induced by IL-6
have been described elsewhere (15). Transgene (
) littermates were used as controls in all experiments.
Oxygen Exposure
Mice were exposed to 100% oxygen in a 50 × 50 × 30-cm airtight chamber and the fractional inspired O2 concentration in the chamber was monitored with an inline oxygen analyzer (Vascular Technology, Inc., Chelmsford, MA) as described elsewhere (16).
Histologic Analysis
Transgenic and wild-type littermate control mice were killed, the right heart was perfused with saline, the trachea was cannulated, and the lungs were inflated to 25 cm of pressure with formalin. They were then fixed in 3% formalin and paraffin-embedded. Trichrome and hematoxylin and eosin stains were done on 5-µ sections in the Department of Pathology at Yale University School of Medicine.
Electron Microscopy
Lungs were isolated and the trachea was cannulated as described earlier. The lungs were then perfused in situ to 25 cm water pressure with 3.5% glutaraldehyde and postfixed for 24 h in 3.5% glutaraldehyde, and representative areas were embedded in epon. Ultrathin sections of embedded tissue were prepared, stained with 2% uranyl acetate and OsO4, and examined using a Phillips EM300 electron microscope.
BAL
After anesthesia, a median sternotomy was performed and the
trachea was transected. BAL was performed by instilling 0.6 ml of phosphate-buffered saline (PBS) and gently aspirating back. This was repeated three times. The samples were pooled and centrifuged, and the cell-free BALF was stored at
70°C until used.
The total protein concentration in the BALF was measured using
the Bio-Rad D.C. Protein Assay (Bio-Rad Labs, Hercules, CA).
Lung Tissue Homogenates
After anesthesia, a median sternotomy was performed, the aorta and inferior vena cava were transected, and the right ventricle was perfused with cold PBS to clear intravenous blood from the lungs. The lungs were then removed and homogenized, in either Tris-HCl (pH 7.4) or a potassium phosphate (pH 7.4) buffer in the presence of protease inhibitors, and centrifuged.
Lung Lipid Peroxidation
Oxidative stress can lead to lipid peroxidation and the subsequent generation of aldehydes that are formed when lipid hydroperoxides break down in biologic systems. The aldehydes most intensively studied so far are the 4-hydroxyalkenals (4-hydroxynonenal, 4-hydroxyhexenal) and malonaldehydes (such as malondialdehyde [MDA]). The assay that was used for tissue lipid peroxidation depends on the production of MDA, a three-carbon degradation product of lipid peroxidation. Detection of lung MDA was done colorimetrically by evaluating levels of thiobarbituric acid-reactive substances in whole-lung homogenates (17). Lungs were isolated and perfused with ice-cold 0.9% NaCl, and homogenates were prepared in ice-cold 20 mM Tris-HCl (pH 7.4). The homogenates were then centrifuged at 3,000 × g at 4°C for 10 min, and 200 µl of the supernatant were removed for the assay. Lipid peroxidation was assessed with a standard methodology that quantitates the interaction of a chromogenic reagent with malonaldehyde and 4-hydroxyalkenals (17) using the LPO-586 kit (Calbiochem, San Diego, CA). The LPO-586 Assay used in this analysis uses the chromogenic reagent N-methyl-2-phenylindole at 45°C. One molecule of either MDA or 4-hydroxyalkenal reacts with two molecules of N-methyl-2-phenylindole to yield a stable chromophore with maximal absorbance at 586 nm. The LPO-586 reaction, when catalyzed with methanesulfonic acid (as in our studies) can be used to assay MDA plus 4-hydroxyalkenals. When concentrated HCl is used as the catalyst, MDA alone, without interference with 4-hydroxyalkenals, is measured. Data are expressed as µM of products of lipid peroxidation in 200 µl of a 20% wt/vol solution of lung homogenate.
Superoxide Dismutase Analysis
The activities of copper/zinc superoxide dismutase (CuZnSOD) and manganese SOD (MnSOD) were assayed spectrophotometrically and by gel electrophoresis.
Spectrophotometric assay. Lung homogenates were prepared in a potassium phosphate (pH 7.4) buffer as described earlier, and cells were disrupted by sonication (Branson Sonifier; Branson Sonic Power, Danbury, CT) using three 15-s bursts at 4°C. A competitive inhibition assay was performed using hypoxanthine-xanthine oxidase-generated O2· to reduce nitroblue tetrazolium (NBT) monitored spectrophotometrically at 560 nm. Inhibition of NBT reduction to 50% of maximal was defined as 1 unit of SOD activity (18). Inhibition of CuZnSOD activity by 5 mM potassium cyanide allowed differentiation of CuZnSOD and MnSOD.
Gel electrophoresis. The SODs were also assayed using the gel
electrophoresis method of Beauchamp and Fridovich (19). This assay is based on the ability of SOD in a polyacrylamide gel to inhibit the reduction of NBT by superoxide anion generated using photochemically reduced riboflavin. Lung homogenates were
prepared in 3 ml potassium phosphate buffer and 1.0 mM ethylenediaminetetraacetic acid, sonicated for 3 min, and centrifuged
at 15,000 × g. Equal amounts of protein were run in a 10% polyacrylamide gel until the bromophenol blue marker dye came off
the end of the apparatus. The gel was then placed in a solution of
2.45 × 10
3 M NBT for 20 min; immersed in a N,N,N',N'-tetra-methyletholynediamine, riboflavin, and potassium phosphate solution for 15 min; and illuminated with a 15-W fluorescent light
for 15 min. During illumination, the gels became uniformly blue
except for areas containing SOD. Dilutions of purified Escherichia coli MnSOD and bovine erythrocyte CuZnSOD were used
to generate standard curves, and the lung-extract MnSOD and
CuZnSOD activities were measured from the linear regions of
these curves. Assessments were done in the presence and absence of potassium cyanide to allow MnSOD and CuZnSOD to be differentiated.
TUNEL Analysis
Terminal deoxyribonucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling (TUNEL) analysis was performed as described by our laboratories (20). In brief, tissue sections (4 to 5 µm) were mounted onto slides pretreated with 3-aminopropylethoxysilane. Slides were baked and washed in fresh xylene, rehydrated through a series of graded alcohols, and washed in distilled water. For TUNEL assay, the tissue sections were treated with proteinase K and terminal transferase and then labeled with rhodamine-conjugated antidigoxigenin. All reagents were obtained from Boehringer Mannheim (Indianapolis, IN). Tissue sections were counterstained with 4', 6-diamidine-2-phenylindole-dihydrochloride (DAPI). To quantify the extent of TUNEL- positive cells in the mouse lung, samples were illuminated with ultraviolet light to visualize either TUNEL-positive nuclei (590 nm) or total DAPI-stained nuclei (420 nm). Images were captured with a CCD video camera. Uniform camera control settings were used for image capture, and image threshholding was identical for all images. The captured images were analyzed using the Metamorph system (Universal Imaging, West Chester, PA) on a personal computer. At least 25 fields were analyzed from at least three individuals at each time point. The TUNEL-positive index was calculated as the percent of TUNEL-positive nuclei divided by the DAPI-staining nuclei.
Western Blots
Western blot analysis was performed using the protein fraction of lung homogenates. Equal quantities of test and control samples (20 to 50 µg) and recombinant protein standards were fractionated by electrophoresis in a 5% stacking and 12% resolving sodium dodecyl sulfate polyacrylamide gel for 1 h at 110 mV. The proteins were then transferred onto nitrocellulose membranes, which were blocked overnight with 10% nonfat milk, washed with 0.05% Tween in PBS, and incubated with appropriate primary antibodies. Monoclonal antibodies (mAbs) against Bcl-2 were obtained from Trevigen, Inc. (Gaithersburg, MD) and Zymed Labs (San Francisco, CA) and used at a dilution of 1:5,000. The positive control protein for mouse Bcl-2 was a mouse M1 cell lysate obtained from PharMingen (San Diego, CA). mAb against mouse TIMP-1 was obtained from Oncogene Research Products (Cambridge, MA) and used at a dilution of 1 µg/ml. The secondary antibody was goat antimouse immunoglobulin G (Pierce Labs, Rockford, IL) (1:10,000; 1 h). The protein bands were imaged using an enhanced chemiluminescence kit (Pierce Labs) and exposed for 30 to 120 s on Kodak Biomax MR film (Eastman Kodak, Rochester, NY). Equal protein loading was confirmed by Coomassie blue staining of all gels.
Statistical Analysis
Data are expressed as means ± standard error of the mean
(SEM). Normally distributed data were assessed for significance
by Student's t test or analysis of variance, as appropriate. Data that were not normally distributed were assessed for significance by the Wilcoxon rank sum test. Differences in survival between transgene (+) and (
) mice were assessed using
2 analysis.
| |
Results |
|---|
|
|
|---|
Effect of IL-6 on Survival
To determine if IL-6 has the ability to ameliorate oxygen toxicity, we compared the survival in 100% O2 of transgene (+) CC10-IL-6 mice with their wild-type littermate controls. In keeping with observations from our laboratory and others (1, 16, 21), all wild-type mice died within 72 to 96 h of 100% O2 exposure. In contrast, the transgene (+) mice were remarkably resistant to hyperoxia (Figure 1). All transgene (+) mice lived for more than 8 d, and more than 90% survived for longer than 12 d (Figure 1). During this exposure interval, the transgene (+) mice demonstrated normal behavior and normal levels of activity.
|
Effect of IL-6 on Lung Histology
To further understand the mechanism(s) of IL-6-induced
protection in the setting of hyperoxia, we compared the gross
and microscopic features of the lungs of transgene (+) and
(
) mice after exposure to 100% O2 for 72 h. On gross examination, the lungs of the transgene (
) mice appeared boggy
and hemorrhagic with copious edema fluid upon transection
of the trachea. In contrast, the transgene (+) lungs were unchanged from baseline. Microscopically, 72 h of 100% O2 exposure induced a mild neutrophilic infiltrate, capillary congestion, and alveolar hemorrhage in transgene (
) mice, but not in the transgene (+) littermates (data not shown).
Ultrastructurally, 48 h of 100% O2 exposure caused extensive cell damage, manifest as membrane swelling, ruffling, and bleb formation in the lungs of the transgene (
)
animals. These changes were even more apparent after
72 h of hyperoxia (Figure 2). In contrast, the membranes
of the transgene (+) animals had a normal ultrastructural
appearance, even after 8 to 10 d of 100% O2 exposure (Figure 2 and data not shown).
|
Effect of IL-6 on Alveolar-Capillary Protein Leakage
To further characterize the effects of IL-6, we compared the
levels of protein in the BALF from transgene (+) mice and
wild-type littermate controls. At baseline, similar levels of
BALF protein were detected in transgene (+) and wild-type
mice. In contrast, exposure to 100% O2 caused a significant
increase in alveolar-capillary leakage and BALF protein.
This response was significantly greater in transgene (
) than
in the transgene (+) mice. After exposure to 100% O2 the
BALF from transgene (
) and (+) mice contained 3.89 ± 0.57 and 1.17 ± 0.17 mg/ml of protein, respectively (P < 0.05)
(Figure 3). These studies demonstrate that IL-6 decreases 100% O2-induced alveolar-capillary protein leakage.
|
Effect of IL-6 on Lung Lipid Peroxidation
Because toxic concentrations of oxygen mediate their effects, in part via lipid peroxidation, we compared the levels of lipid peroxidation in lung homogenates from transgene (+) mice and transgene (
) littermate controls both
before and after exposure to hyperoxia. At baseline, the
levels of lipid peroxidation by-products in the lungs of
transgene (
) mice and transgene (+) mice were similar (Figure 4). After 72 h of exposure to 100% oxygen there
was a significant increase in the level of lung lipid peroxidation in the transgene (
) mice (P < 0.001). In contrast,
the transgene (+) mice did not show a statistically significant increase in the level of lipid peroxidation (P = 0.06).
In addition, after 72 h of 100% O2 exposure, the levels of
lipid peroxidation by-products in lungs from transgene
(
) animals were significantly greater than in lungs from
transgene (+) animals (P < 0.008) (Figure 4). This demonstrates that the transgenic overexpression of IL-6 blunts 100% O2-induced membrane lipid peroxidation.
|
Effect of IL-6 on Antioxidant Enzymes
SOD enzymes are believed to play a significant role in
the protection of the lung from hyperoxia (22). To address the possibility that IL-6-induced protection is due to
IL-6-induced alterations in SOD activity, we measured
the activities of MnSOD and CuZnSOD in equal amounts
of lung tissue from transgene (
) and (+) mice before and
after exposure to 100% oxygen. Both gel electrophoresis and spectrophotometric approaches failed to reveal significant differences in MnSOD or CuZnSOD activities before and after 72 h of 100% oxygen exposure (data not
shown). Thus, IL-6 confers protection in the setting of
hyperoxic lung injury via a mechanism that is largely independent of the major protective enzymes MnSOD and CuZnSOD.
Effect of IL-6 on Nuclear DNA Fragmentation
Hyperoxic lung injury is characterized by a cell-death response with features of apoptosis and necrosis (4, 5). Because both can be associated with DNA fragmentation
(27) we used TUNEL assays to assess the levels of DNA
fragmentation in transgene (
) and (+) mice before and
after exposure to 100% O2. In these studies, the data are
expressed as a fragmentation index, which is the percentage of total nuclei that were TUNEL-positive. At baseline,
only rare TUNEL-positive cells were noted and similar numbers of TUNEL-positive cells were noted in transgene
(
) and (+) mice (data not shown). Exposure to 100% O2
for 72 h caused a significant increase in the labeling of stromal cells in transgene (
) and (+) mice (Figure 5). Interestingly, the fragmentation index of transgene (
) mice
was significantly greater than that of transgene (+) animals
(27.3 versus 15.1, respectively) (Figure 5) (P < 0.05). This
demonstrates that the protective effects of IL-6 are associated with decreased cell death and DNA fragmentation.
|
Effect of IL-6 on Bcl-2 and BAX
The Bcl-2 family of proteins are potent regulators of many
pathways of apoptosis (reviewed in References 28 and 29)
and necrosis (30, 31). Bcl-2 also has antioxidant properties
in some, but not all, experimental systems (32). This
led us to speculate that Bcl-2 proteins might play a role in
the IL-6-induced protection that was noted. To further investigate this possibility, we used immunoblot analysis to
characterize the accumulation of selected Bcl-2 proteins in
transgene (+) and (
) mice before and after exposure to
100% O2. Comparisons of Bcl-2 and BAX were undertaken because of their known abilities to inhibit and stimulate cell-death responses, respectively (28, 29). Our data
demonstrate impressive differences in the levels of Bcl-2
in transgene (
) and (+) mice (Figure 6). At baseline, the
levels of Bcl-2 were significantly greater in (+) than in (
)
mice. Exposure to 100% O2 for 72 h did not significantly
alter this relationship. In contrast, the levels of BAX were
similar in transgene (
) and (+) mice before and after O2
exposure (Figure 6). These data demonstrate that the CC-10-IL-6 transgenic mice have higher levels of Bcl-2, but not BAX, in lung tissue compared with transgene (
) littermate controls.
|
Effect of IL-6 on TIMP-1
TIMP-1 is an important inhibitor of matrix metalloproteinases (MMPs) in many tissue-inflammatory responses
(reviewed in Reference 35). Recently, TIMP-1 has also
been shown to have antioxidant properties and to inhibit
cellular apoptosis (36). To investigate the possible role of
TIMP-1 in the IL-6-induced protection that was noted, we
used immunoblot analysis to characterize the accumulation of TIMP-1 protein in the lungs from transgene (
)
and (+) mice before and after 72 h of 100% O2 exposure.
These studies demonstrated the heightened accumulation
of TIMP-1 protein in the lungs from transgene (+) as versus the transgene (
) mice (Figure 7). Exposure to 100%
O2 did not significantly alter this relationship (Figure 7).
|
| |
Discussion |
|---|
|
|
|---|
To determine whether exogenous IL-6 has protective effects in the setting of hyperoxic lung injury we compared
the survival and indices of pulmonary injury in transgenic
mice that overexpress IL-6 in a lung-specific manner with
their transgene (
) littermate controls. These studies demonstrated that IL-6 diminishes hyperoxic lung injury. This
protection was manifest as significantly enhanced survival
and decreased tissue injury, alveolar-capillary protein leakage, and lung lipid peroxidation. These studies also
showed that exposure to 100% O2 causes a prominent
TUNEL-positive cell-death response and that IL-6 inhibits this cytopathic reaction. Lastly, our investigations demonstrated that this IL-6-induced effect is not associated
with alterations in SOD activity that can account for this
protection, but is associated with elevated levels of the
cell-death inhibitors Bcl-2 and TIMP-1.
IL-6 is a well-recognized mediator of both acute and chronic tissue inflammation that is induced during acute lung injury (37, 38). It also has anti-inflammatory properties, is protective in models of tissue injury, and can ameliorate tissue damage in a variety of lung injury systems (7). Our studies are the first to show that the expression of IL-6 can minimize the injury caused by 100% O2. Since IL-1 and TNF induce IL-6 elaboration by a variety of lung stromal cells (39), these observations suggest that IL-6 may be an important mediator of the protective effects of IL-1 and TNF in hyperoxic lung injury (40). These observations also complement those of Tsan and colleagues (42), who demonstrated that IL-6 can interact with IL-1 and TNF to mediate protection from hyperoxic lung injury. There are, however, a number of important differences between our findings and those of Tsan and associates that deserve comment. First, in contrast to Tsan and coworkers, our studies showed that IL-6 expression by itself is sufficient to induce this protective state. In addition, the protection that we noted did not appear to be mediated by MnSOD, whereas that described by Tsan and colleagues was associated with the induction of and potentially mediated by this important antioxidant enzyme. The explanation for these different results is not fully clear. They may, however, reflect the different experimental protocols that were used. Our studies used overexpression transgenic technology which, by definition, exposes pulmonary tissues to IL-6 for a prolonged time period before the initiation of hyperoxic conditions. Tsan and associates (42) administered IL-6 via tracheal insufflation, and administered the cytokine and initiated the hyperoxic exposure simultaneously. Therefore, their animals were exposed to IL-6 for shorter intervals and probably had lower concentrations of IL-6 at sites of lung injury. When viewed in combination, however, both studies support the contention that IL-6 has important protective effects in this injury state.
Pulmonary oxygen toxicity is mediated by reactive oxygen intermediates (ROIs), which damage membrane proteins and lipids, polysaccharides, and DNA. Thus, to protect lung tissue from hyperoxic injury, one needs to limit the generation of ROIs, augment antioxidant defenses, or induce cytoprotective responses that diminish tissue susceptibility to ROI-induced damage. Our studies showed that IL-6 decreases 100% O2-induced tissue injury and begins to investigate the mechanism(s) of this protective response. The mechanistic studies do not address the possibility that IL-6 might limit ROI generation. They do, however, demonstrate that IL-6-induced protection is not associated with alterations in the levels of MnSOD or CuZnSOD that could explain this protective response. This is in keeping with earlier studies from our laboratory showing that the protection induced by IL-11 in the setting of 100% O2 exposure is mediated by a SOD-independent mechanism (16) and studies that demonstrate that MnSOD is an important, but not the only, protective mechanism controlling oxidant-mediated lung injury (25, 26, 43, 44). Importantly, these studies show that IL-6 is a prominent inhibitor of 100% O2-induced cell death and DNA fragmentation. This observation is in accord with documented ability of IL-6-type cytokines to inhibit apoptotic cell death in a number of experimental systems (14, 45). When viewed in combination, these studies suggest that the protective effects of IL-6 are mediated, at least partially, by the ability of IL-6 to induce cytoprotective responses in end-organ tissues that diminish their susceptibility to ROI-induced injury.
At sites of tissue injury, cells can die via necrosis or apoptosis. Traditionally, these processes have been considered operationally and mechanistically distinct cell-death responses (49, 50). However, recent studies have demonstrated that the distinction between apoptosis and necrosis may not be as crisp as once thought. This blurring is the result of studies showing that apoptosis-like DNA laddering can be seen in cells undergoing necrosis, that known inducers of apoptosis can cause cells to die via necrosis, that apoptosis and necrosis can be induced by the same agent in the same cell population, and that apoptosis and necrosis can be present simultaneously in tissues experiencing the same injury (4, 5, 27, 49, 51). Early studies of pulmonary oxygen toxicity demonstrated cell swelling and other features compatible with cellular necrosis (1, 52, 53). More recent studies have demonstrated DNA fragmentation compatible with apoptosis and suggested that the cell-death response in oxygen toxicity has features of both processes (4, 5). Although the exact nature of this cell-death response is still being investigated, it is clear from our studies that IL-6 has impressive cytoprotective properties in this injury system. To gain insight into the mechanism(s) of this protection, we determined whether altered IL-6 altered the accumulation of proteins that regulate these responses. Bcl-2 was a particularly attractive candidate because it has been shown to inhibit apoptosis and necrosis (28, 49, 54). Our studies demonstrate that IL-6 is a potent inducer of pulmonary Bcl-2 accumulation. This supports the hypothesis that IL-6- induced Bcl-2 may play an important role in the protection that was noted. Additional investigation will be required to test the validity of this hypothesis. If Bcl-2 is shown to play an important role in this protective response, additional investigations will also be required to determine whether the beneficial effects of Bcl-2 are the result of its ability to alter cell-death responses and/or is ability to act as an antioxidant, as has been demonstrated in some, but not all, experimental systems (32).
The matrix-degrading activities of MMPs are controlled by a variety of inhibitors, including the members of the TIMP family. Studies of TIMP-1, the original member of this family, have focused almost exclusively on its ability to inhibit MMP activity. More recent studies, however, have shown that TIMP-1 may have a number of other important biologic roles at sites of injury. Particularly relevant to the present investigations are the studies of Guedez and colleagues (36) demonstrating that TIMP-1 can inhibit apoptosis via a mechanism that is independent of its anti-MMP activity. Because it is reasonable to believe that an agent that preserves lung scaffolding while decreasing cell death could be protective in the setting of oxygen toxicity, studies were undertaken to determine whether IL-6 regulated TIMP-1 in lung structures. These studies show that IL-6 is a potent stimulator of pulmonary TIMP-1 accumulation. This observation is in accord with prior in vitro investigations demonstrating that IL-6-type cytokines are potent inducers of TIMP-1 elaboration (55). These findings support the hypothesis that IL-6-induced protection in the setting of 100% O2 exposure is mediated, in part, by the induction of TIMP-1. When the Bcl-2 and TIMP-1 data are viewed in combination, it is reasonable to speculate that IL-6-induced protection is mediated via a number of different mechanisms and that the multimechanistic nature of the effects of IL-6 are responsible, at least in part, for the impressively potent protection that is conferred by IL-6 in this injury setting.
In summary, our studies show that IL-6 has impressive protective effects in the setting of 100% O2-induced acute lung injury. Toxic concentrations of oxygen are given to large numbers of patients throughout the world on a daily basis. Oxidant-induced organ damage also plays a major role in the pathogenesis of a variety of other pulmonary and nonpulmonary disorders. Our studies suggest that IL-6-type cytokines can improve the therapeutic index of hyperoxic O2 administration and favorably alter the course of oxidant-mediated disorders. Additional investigation is warranted to determine whether exogenously administered IL-6 is useful therapeutically or prophylactically in the setting of hyperoxia-induced lung injury and other oxidant-induced injury states.
| |
Footnotes |
|---|
Address correspondence to: Jack A. Elias, M.D., Section of Pulmonary and Critical Care Medicine, Yale University School of Medicine, Dept. of Internal Medicine, 333 Cedar St./105 LCI, New Haven, CT 06520-8057. E-mail: Jack.elias{at}yale.edu
(Received in original form May 14, 1999 and in revised form December 1, 1999).
Abbreviations: bronchoalveolar lavage, BAL; BAL fluid, BALF; transgenic mice in which IL-6 was selectively overexpressed in the lung, CC10-IL-6 mice; 4',6-diamidine-2-phenylindole-dihydrochloride, DAPI; interleukin, IL; malondialdehyde, MDA; matrix metalloprotease, MMP; nitroblue tetrazolium, NBT; phosphate-buffered saline, PBS; reactive oxygen intermediate, ROI; superoxide dismutase, SOD; tissue inhibitor of metalloproteinase, TIMP; tumor necrosis factor, TNF; terminal deoxyribonucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling, TUNEL.Acknowledgments: The authors thank the investigators who provided the reagents, and thank Ms. Kathleen Bertier for her excellent assistance. This work was supported by grants R01-HL-36708, P50-HL-56389, and R01-HL-61904 to one author (J.A.E.) and grant K08-HL-03888 to one author (A.B.W.) One author (A.B.W.) is a Parker B. Francis Scholar.
| |
References |
|---|
|
|
|---|
1. Smith, L.. 1985. Hyperoxic lung injury: biochemical, cellular, and morphologic characterization in the mouse. J. Lab. Clin. Med. 106: 269-273 [Medline].
2. Crapo, J. D.. 1986. Morphologic changes in pulmonary oxygen toxicity. Annu. Rev. Physiol. 48: 721-731 [Medline].
3. Crapo, J. D., B. E. Barry, H. A. Foscue, and J. Shelburne. 1980. Structural and biochemical changes in rat lungs occurring during exposure to lethal and adaptive doses of oxygen. Am. Rev. Respir. Dis. 122: 123-143 [Medline].
4.
Barazzone, C.,
S. Horowitz,
Y. R. Donati,
I. Rodriguez, and
P. F. Piguet.
1998.
Oxygen toxicity in mouse lung: pathways to cell death.
Am. J. Respir.
Cell Mol. Biol.
19:
573-581
5.
Kazzaz, J. A.,
J. Xu,
T. A. Palaia,
L. Mantell,
A. M. Fein, and
S. Horowitz.
1996.
Cellular oxygen toxicity: oxidant injury without apoptosis.
J. Biol.
Chem.
271:
15182-15186
6. Heinrich, P. C., I. Behrmann, G. Muller-Newen, F. Schaper, and L. Graeve. 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334: 297-314 .
7.
Tilg, H.,
E. Trehu,
M. B. Atkins,
C. A. Dinarello, and
J. W. Meir.
1994.
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor
p55.
Blood
83:
113-118
8. Xing, Z., J. Gauldie, G. Cox, H. Baumann, M. Jordana, X. Lei, and M. Achong. 1998. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101: 311-320 [Medline].
9.
Shingu, M.,
S. Miyauchi,
Y. Nagai,
C. Yasutake, and
K. Horie.
1995.
The
role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation.
Br.
J. Rheumatol.
34:
101-106
10. Shingu, M., T. Isayama, C. Yasutake, T. Naono, M. Nobinaga, K. Tomari, K. Horie, and Y. Goto. 1994. Role of oxygen radicals and IL-6 in IL-1- dependent cartilage matrix degradation. Inflammation 18: 613-623 [Medline].
11. Ulich, T. R., S. Yin, K. Guo, E. Yi, D. Remick, and J. del Castillo. 1991. Intratracheal injection of endotoxin and cytokines: II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am. J. Pathol. 138: 1097-1101 [Abstract].
12.
Mizuhara, H.,
E. O'Neill,
N. Seki,
T. Ogawa,
C. Kusonoki,
K. Otsuka,
S. Satoh,
M. Niwa,
H. Senoh, and
H. Fujiwara.
1994.
T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by
interleukin-6.
J. Exp. Med.
179:
1529-1537
13. Jordan, M., I. G. Otterness, R. Ng, A. Gessner, M. Rollinghoff, and H. Beuscher. 1995. Neutralization of endogenous IL-6 suppresses induction of IL-1 receptor antagonist. J. Immunol. 154: 4081-4090 [Abstract].
14. Rollwagen, F. M., Z. Y. Yu, Y. Y. Li, and N. D. Pacheco. 1998. IL-6 rescues enterocytes from hemorrhage induced apoptosis in vivo and in vitro by a Bcl-2 mediated mechanism. Clin. Immunol. Immmunopathol. 89: 205-213 [Medline].
15. DiCosmo, B. F., G. G. Geba, D. Picarella, J. A. Elias, J. A. Rankin, B. R. Stripp, J. A. Whitsett, and R. A. Flavell. 1994. Airway epithelial cell expression of interleukin-6 transgenic mice: uncoupling of airway inflammation and bronchial hyperreactivity. J. Clin. Invest. 94: 2028-2035 .
16. Waxman, A. B., O. Einarsson, T. Seres, R. G. Knickelbein, J. B. Warshaw, R. Johnson, R. J. Homer, and J. A. Elias. 1998. Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J. Clin. Invest. 101: 1970-1982 [Medline].
17. Esterbauer, H., and K. H. Cheeseman. 1990. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 186: 407-421 [Medline].
18. Spitz, D. R., and L. W. Oberley. 1989. An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal. Biochem. 179: 8-18 [Medline].
19. Beauchamp, C., and I. Fridovich. 1971. Superoxide dismutase: improved assays and as assay applicable to acrylamide gels. Anal. Biochem. 44: 276-287 [Medline].
20. Mantell, L., J. Kazzaz, J. Xu, T. Palaia, B. Piedboeuf, S. Hall, G. C. Rhodes, G. Niu, A. M. Fein, and S. Horowitz. 1997. Unscheduled apoptosis during acute lung injury. Cell Death Differ. 4: 600-607 . [Medline]
21.
Jensen, J.,
H. Pogrebniak,
I. Pass,
C. Buresh,
M. Merino,
D. Kauffman,
D. Venzon,
N. Langstein, and
J. Norton.
1992.
Role of tumor necrosis factor
in oxygen toxicity.
J. Appl. Physiol.
72:
1902-1907
22.
Wong, G. H. W., and
D. V. Goeddel.
1988.
Induction of manganese superoxide dismutase by tumor necrosis factor: possible protective mechanism.
Science
242:
941-944
23. Masuda, A., D. L. Longo, Y. Kobayashi, E. Appella, J. J. Oppenheim, and K. Matsushima. 1988. Induction of mitochondrial manganese superoxide dismutase by interleukin-1. FASEB J. 2: 3087-3091 [Abstract].
24. Shiki, Y., B. O. Meyerick, K. L. Brigham, and I. M. Burr. 1989. Endotoxin increases superoxide dismutase in cultured bovine pulmonary endothelial cells. Am. J. Physiol. 252: C436-C440 .
25.
Tsan, M. F.,
J. E. White,
T. A. Santana, and
C. Y. Lee.
1990.
Tracheal insufflation of tumor necrosis factor protects rats against oxygen toxicity.
J.
Appl. Physiol.
68:
1211-1219
26.
Wispe, J. R.,
B. B. Warner,
J. C. Clark,
C. R. Dey,
J. Neuman,
S. W. Glasser,
J. D. Crapo,
L. Y. Chang, and
J. A. Whitsett.
1992.
Human Mn-superoxide dismutase in pulmonary epithelial cells of transgenic mice confers protection from oxygen injury.
J. Biol. Chem.
267:
23937-23941
27. Dong, Z., P. Saikumar, J. M. Weinberg, and M. A. Venkatachalam. 1997. Inter-nucleosomal DNA cleavage triggered by plasma membrane damage during necrotic cell death: involvement of serine but not cysteine proteases. Am. J. Pathol. 151: 1205-1213 [Abstract].
28. Hawkins, C. J., and D. L. Vaux. 1997. The role of Bcl-2 family of apoptosis regulatory proteins in the immune system. Semin. Immunol. 9: 25-33 [Medline].
29.
Reed, J..
1994.
Bcl-2 and the regulation of cell death.
J. Cell Biol.
124:
1-6
30. Tsujimoto, Y., S. Shimizu, Y. Eguchi, W. Kamiike, and H. Matsuda. 1997. Bcl-2 and Bcl-xl block apoptosis as well as necrosis: possible involvement of common mediators in apoptotic and necrotic signal transduction pathways. Leukemia 11: 380-382 .
31. Yamabe, K., S. Shimizu, W. Kamiike, S. Waguri, Y. Eguchi, J. Hasegawa, S. Okuno, Y. Yoshioka, T. Ito, Y. Sawa, Y. Uchiyama, Y. Tsujimoto, and H. Matsuda. 1998. Prevention of hypoxic liver cell necrosis by in vivo human Bcl-2 gene transfection. Biochem. Biophys. Res. Commun. 243: 217-223 [Medline].
32.
Kane, D. J.,
T. A. Sarafian,
R. Anton,
H. Hahn,
E. B. Gralla,
J. S. Valentine,
T. Ord, and
D. E. Bredsen.
1993.
Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species.
Science
262:
1274-1277
33. Hockenberry, D. M., Z. N. Oltvai, X. Yin, C. L. Milliman, and S. J. Korsmeyer. 1993. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251 [Medline].
34. Bruce-Keller, A. J., J. G. Begley, W. Fu, D. A. Butterfield, D. E. Bredesen, J. B. Hutchins, K. Hensely, and M. P. Mattson. 1998. Bcl-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid beta-peptide. J. Neurochem. 70: 31-39 [Medline].
35. Gomez, D. E., D. F. Alonso, H. Yoshiji, and U. P. Thorgeirsson. 1997. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74: 111-122 [Medline].
36. Guedez, L., W. G. Stetler-Stevenson, L. Wolff, J. Wang, P. Fukushima, A. Mansoor, and M. Stetler-Stevenson. 1998. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J. Clin. Invest. 102: 2002-2010 [Medline].
37.
Gadient, R. A., and
P. H. Patterson.
1999.
Leukemia inhibitory factor, interleukin-6, and other cytokines using the GP130 transducing receptor:
roles in inflammation and injury.
Stem Cells
17:
127-137
38.
Meduri, G. U.,
S. Headley,
G. Kohler,
F. Stentz,
E. Tolley,
R. Umberger, and
K. Leeper.
1995.
Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1b and IL-6 levels are consistent and efficient predictors of outcome over time.
Chest
107:
1062-1073
39.
Elias, J. A., and
V. Lentz.
1990.
Interleukin-1 and tumor necrosis factor synergistically stimulate fibroblast interleukin-1-
production.
Am. J. Respir.
Cell Mol. Biol.
3:
13-20
.
40. Tsan, M. F., J. E. White, T. A. Santana, and C. Y. Lee. 1990. Tracheal insufflation of tumor necrosis factor protects rats against oxygen toxicity. J. Appl. Physiol. 68: 1211-1219 .
41.
Tsan, M. F.,
C. Y. Lee, and
J. E. White.
1991.
Interleukin 1 protects rats
against oxygen toxicity. 1991.
J. Appl. Physiol.
71:
688-697
42.
Tsan, M. F.,
J. White,
P. Del Vecchio, and
J. B. Shaffer.
1992.
IL-6 enhances
TNF-alpha- and IL-1-induced increase of Mn superoxide dismutase mRNA
and O2 tolerance.
Am. J. Physiol.
263:
L22-L26
43. Choi, A., S. Sylvester, L. Otterbein, and N. J. Holbrook. 1995. Molecular responses to hyperoxia in vivo: relationshhip to increased tolerance in aged rats. Am. J. Respir. Cell Mol. Biol. 13: 74-82 [Abstract].
44.
Ho, Y. S..
1994.
Transgenic models for the study of lung biology and disease.
Am. J. Physiol.
266:
L319-L353
45. Teague, T. K., P. Marrack, J. W. Kappler, and A. T. Vella. 1997. IL-6 rescues resting mouse T cells from apoptosis. J. Immunol. 158: 5791-5796 [Abstract].
46.
Schwarze, M. M., and
R. G. Hawley.
1995.
Prevention of myeloma cell apoptosis by ectopic Bcl-2 expression or interleukin-6 mediated up-regulation
of Bcl-xl.
Cancer Res.
55:
2262-2265
47.
Du, X.,
Q. Liu,
Z. Yang,
A. Orazi,
F. J. Rescorla,
J. L. Grosfeld, and
D. A. Williams.
1997.
Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis.
Am. J. Physiol.
272:
G545-G552
48.
Sheng, Z.,
K. Knowlton,
J. Chen,
J. Hoshijima,
J. H. Brown, and
K. R. Chien.
1997.
Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway.
J. Biol.
Chem.
272:
5783-5791
49. Cohen, J. J.. 1996. Apoptosis and its regulation. Adv. Exp. Med. Biol. 406: 11-20 [Medline].
50. Kroemer, B., P. Petit, N. Zamzami, J. L. Vayssiere, and B. Mignotte. 1995. The biochemstry of programmed cell death. FASEB J. 9: 1277-1287 [Abstract].
51.
Ueda, N.,
P. D. Walker,
S. M. Hsu, and
S. V. Shah.
1995.
Activation of a 15-kDa endonuclease in hypoxia/reoxygenation injury without morphologic
features of apoptosis.
Proc. Natl. Acad. Sci. USA
92:
7202-7206
52. Adamson, I. Y. R., D. H. Bowden, and J. P. Wyatt. 1970. Oxygen poisoning in mice: ultrastructural and surfactant studies during exposure and recovery. Arch. Pathol. 90: 463-472 [Medline].
53. Hinshaw, D. B., J. M. Burger, B. C. Armstrong, and P. A. Hyslop. 1989. Mechanism of endothelial shape change in oxidant injury. J. Surg. Res. 46: 339-349 [Medline].
54.
Zhong, L. T.,
T. Sarafian,
D. J. Kane,
A. C. Charles,
S. P. Mah,
R. H. Edwards, and
D. E. Bredesen.
1993.
Bcl-2 inhibits death of central neural
cells induced by multiple agents.
Proc. Natl. Acad. Sci. USA
90:
4533-4537
55.
Richards, C. D.,
C. Kerr,
M. Tanaka,
T. Hra,
A. Miyajima,
D. Pennica,
F. Botelho, and
C. M. Langdon.
1997.
Regulation of tissue inhibitor of metalloproteinase-1 in fibroblasts and acute phase proteins in hepatocytes in
vitro by mouse oncostatin M, cardiotropin-1, and IL-6.
J. Immunol.
159:
2431-2437
This article has been cited by other articles:
![]() |
G. Matute-Bello, C. W. Frevert, and T. R. Martin Animal models of acute lung injury Am J Physiol Lung Cell Mol Physiol, September 1, 2008; 295(3): L379 - L399. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Quinton, M. R. Jones, B. E. Robson, B. T. Simms, J. A. Whitsett, and J. P. Mizgerd Alveolar Epithelial STAT3, IL-6 Family Cytokines, and Host Defense during Escherichia coli Pneumonia Am. J. Respir. Cell Mol. Biol., June 1, 2008; 38(6): 699 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nechemia-Arbely, D. Barkan, G. Pizov, A. Shriki, S. Rose-John, E. Galun, and J. H. Axelrod IL-6/IL-6R Axis Plays a Critical Role in Acute Kidney Injury J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1106 - 1115. [Full Text] [PDF] |
||||
![]() |
H. Kida, M. L. Mucenski, A. R. Thitoff, T. D. Le Cras, K.-S. Park, M. Ikegami, W. Muller, and J. A. Whitsett GP130-STAT3 Regulates Epithelial Cell Migration and Is Required for Repair of the Bronchiolar Epithelium Am. J. Pathol., June 1, 2008; 172(6): 1542 - 1554. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Matsuzaki, V. Besnard, J. C. Clark, Y. Xu, S. E. Wert, M. Ikegami, and J. A. Whitsett STAT3 Regulates ABCA3 Expression and Influences Lamellar Body Formation in Alveolar Type II Cells Am. J. Respir. Cell Mol. Biol., May 1, 2008; 38(5): 551 - 558. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Choo-Wing, J. H. Nedrelow, R. J. Homer, J. A. Elias, and V. Bhandari Developmental differences in the responses of IL-6 and IL-13 transgenic mice exposed to hyperoxia Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L142 - L150. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bhandari, R. Choo-Wing, R. J. Homer, and J. A. Elias Increased Hyperoxia-Induced Mortality and Acute Lung Injury in IL-13 Null Mice J. Immunol., April 15, 2007; 178(8): 4993 - 5000. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Jain, E. Atochina-Vasserman, H. Kadire, Y. Tomer, A. Inch, P. Scott, R. C. Savani, A. J. Gow, and M. F. Beers SP-D-deficient mice are resistant to hyperoxia Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L861 - L871. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Fabisiak, F. Gao, R. G. Thomson, R. M. Strieter, S. C. Watkins, and J. H. Dauber Mycoplasma fermentans and TNF-beta interact to amplify immune-modulating cytokines in human lung fibroblasts Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L781 - L793. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. F. Barker, N. D. Manzo, K. L. Cotich, R. K. Shone, and A. B. Waxman DNA Damage Induced by Hyperoxia: Quantitation and Correlation with Lung Injury Am. J. Respir. Cell Mol. Biol., September 1, 2006; 35(3): 277 - 288. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. F. Vitiello, R. J. Staversky, S. C. Gehen, C. J. Johnston, J. N. Finkelstein, T. W. Wright, and M. A. O'Reilly p21Cip1 Protection against Hyperoxia Requires Bcl-XL and Is Uncoupled from Its Ability to Suppress Growth Am. J. Pathol., June 1, 2006; 168(6): 1838 - 1847. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. O. Duan and P. J. Simpson-Haidaris Cell Type-specific Differential Induction of the Human {gamma}-Fibrinogen Promoter by Interleukin-6 J. Biol. Chem., May 5, 2006; 281(18): 12451 - 12457. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, S. A. Phelan, Y. Manevich, S. I. Feinstein, and A. B. Fisher Transgenic Mice Overexpressing Peroxiredoxin 6 Show Increased Resistance to Lung Injury in Hyperoxia Am. J. Respir. Cell Mol. Biol., April 1, 2006; 34(4): 481 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Mancuso, G. B. Huffnagle, M. A. Olszewski, J. Phipps, and M. Peters-Golden Leptin Corrects Host Defense Defects after Acute Starvation in Murine Pneumococcal Pneumonia Am. J. Respir. Crit. Care Med., January 15, 2006; 173(2): 212 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
|